ZIKA-001: Safety and Immunogenicity of an Engineered DNA Vaccine Against ZIKA virus infection

BACKGROUND: While Zika virus (ZIKV) infection is typically self-limited, congenital birth defects and Guillain-Barré syndrome are well-described. There are no therapies or vaccines against ZIKV infection. METHODS: ZIKA-001 is a phase I, open label, clinical trial designed to evaluate the safety, sid...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Open Forum Infect Dis
Autors principals: Tebas, Pablo, Roberts, Christine C, Muthumani, Kar, Reuschel, Emma, White, Scott, Khan, Amir S, Racine, Trina, Choi, Hyeree, Zaidi, Faraz, Boyer, Jean, Kudchodkar, Sagar, Park, Young K, Trottier, Sylvie, Remigio, Celine, Krieger, Diane, Kobinger, Gary P, Weiner, David, Maslow, Joel
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2017
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5631827/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofx163.693
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars